---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269986"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:49:48.895399+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial

## Summary
- Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.
- Cash, equivalents, and marketable securities $295.9M as of Sept 30, 2025, expected to fund operations through 2029.
- First participant dosed in Phase 1 trial of oral NLRP3 inhibitor BGE-102; initial SAD data expected by year-end 2025.
- Oral and parenteral APJ agonist programs on track for IND submissions in 2026; U.S. provisional patent filed May 2025.
- Partnerships with Novartis and Lilly advancing as expected.

## SEC filing metadata
- accession: 0001193125-25-269986
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312525269986/0001193125-25-269986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312525269986/bioa-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269986
- JSON: https://secwatch.observer/filing/0001193125-25-269986.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.